Chronicle Pharmabiz: Zim Laboratories to be listed on BSE tomorrow

Nagpur based Zim Laboratories Limited, a leading provider of new drug delivery systems, will be listing on Bombay Stock Exchange (BSE) Main Board on June 8 and will have a price discovery as per trading on the bourses. It is likely to fetch attractive returns for existing shareholders.

The book value price of Zim Labs, promoted by technocrate Dr Anwar Daud is Rs 160 per equity share. Daud and his family has 54 per cent stake in ZIM Labs and the private equity partner Ashmore Alchemy India Advisors has about 22 per cent. Rest is with minority shareholders.

 Original Article

Comments

Post a Comment

Popular posts from this blog

The Financial World: ZIM Laboratories Limited Listing on BSE Main Board

ZIM Laboratories Limited (ZIM) has been listed on the BSE Main Board on June 8, 2018. The book value price of ZIM was Rs 160 per equity share. Anwar Daud, Chairman & Managing Director, told media persons here recently that ZIM is amongst the few global companies to have developed and commercialized the oral film technology, besides also being the first Indian company to manufacture multi-layer thin films that contain more than one API on a single thin strip. Describing ZIM Laboratories as a unique R&D-centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS), he said ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines and the company listing on BSE on June 8 had a price discovery as per trading on the bourses. Original Article
Read more

ZIM’s exclusive Oral Thin Film manufacturing technology - ‘Thinoral®’

Image
Fast dissolving oral films are thin & elegant films that dissolves instantaneously when kept on the tongue. These films do not require water for their administration. The films are instantly wettable, rapidly dissolving, non-sticky, non-tacky, and non-curving. As much as 100 mg of active drug can be loaded on these films. A patent application has already been filed in various countries. The technology has been registered with the name ‘ Thinoral ® ’. It is suitable for delivery of thermo labile actives, also both solid and liquid drugs can be formulated into thin film delivery platform.The dosage form is ideal for special need patient population segment. There are many patients who can’t swallow their medicines. ZIM has so far developed about 30 products in Orally Disintegrating Films dosage form and many more are in pipeline. About ZIM Labs ZIM Laboratories Limited is an innovative drug delivery solutions providing company targeting patient convenience and adheren
Read more

APN News: ZIM Laboratories Limited to List on BSE Main Board on June 8, 2018

ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS). Promoted by Technocrat Dr. Anwar Daud, the company has a Unique R&D focused business model helping customers with product development, co-development, out licensing, manufacturing, supplies and marketing support with a strong IP base – 26 inventions with 53 patent filings and 174 clients across 45 countries. Original Article  
Read more